San Francisco based startup Prellis Biologics announced it raised new funding to speed up the wait for human organ transplants and improve drug therapies.
The startup announced it has raised $8.7 million in Series A funding from True Ventures, IndieBio and Khlosa Ventures.
The startup has raised more than $10 million since its 2016 launch.
The company developed the first holographic printing system that can match and accurately replicate human organ and tissue structures for research ad development and organ transplanting. The company plans to help minimize the shortage of worldwide human organ for transplanting by using this printing technology.